Wegovy Price Cut of Up to 37% in India

Novo Nordisk has cut the Indian price of its weight-loss drug Wegovy (semaglutide) by up to 37%.
Why this matters:

• Affordability is a major barrier in real-world practice; price reductions can increase adoption and allow more patients access.

• However, it also raises expectations: if we use the drug more widely, monitoring systems for side-effects, patient adherence and outcome tracking must be robust.

• This move could prompt competitive responses from other weight-loss/GLP-1 class drugs, helping patients ultimately.

• As a prescribing physician, I need to update my practice protocols: who qualifies, how to monitor, what side-effects to watch for, what counselling to give on lifestyle plus therapy.